Shelle Barber, DO
Family Medicine · Arlington, TXNPI 1750580262
Payments from drug & device makers
Across 240 payments — averaging $16.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Lilly USA, LLC$435
- Boehringer Ingelheim$379
- AstraZeneca$254
- Novo Nordisk$241
- Astellas Pharma US Inc$221
- plus $1K from 29 others
What the payments were for
- Food & beverage$3,89498%
- Education$962%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,003 |
| Lilly USA, LLC | 25 | $435 |
| Boehringer Ingelheim | 21 | $379 |
| AstraZeneca | 15 | $254 |
| Novo Nordisk | 13 | $241 |
| Astellas Pharma US Inc | 8 | $221 |
| Bayer | 10 | $189 |
| Abbott | 8 | $178 |
| Exact Sciences | 7 | $157 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $116 |
| Johnson & Johnson | 8 | $103 |
| GSK | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $66 |
| Idorsia Pharmaceuticals US Inc | 3 | $62 |
| Pfizer | 3 | $48 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Kowa Pharmaceuticals America, Inc. | 3 | $43 |
| Novartis | 2 | $35 |
| Merck | 2 | $32 |
| Dexcom, Inc. | 2 | $32 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $28 |
| Seqirus USA Inc | 1 | $21 |
| Tris Pharma Inc | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $19 |
| Phathom Pharmaceuticals, Inc. | 1 | $19 |
| Medtronic | 1 | $17 |
| Sunovion Pharmaceuticals Inc. | 2 | $17 |
| Althera Pharmaceuticals LLC | 1 | $16 |
| Sanofi Pasteur Inc. | 1 | $14 |
| Amgen | 1 | $14 |
| Echosens North America, Inc. | 1 | $14 |
| Shire North American Group Inc | 1 | $13 |
| Ironwood Pharmaceuticals, Inc | 1 | $13 |
| Genentech USA, Inc. | 1 | $12 |
| Teva Pharmaceuticals USA, Inc. | 1 | $12 |
How this compares
$3,990 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 101 | $102,071 |
| TrulicityDulaglutide | 62 | $92,267 |
| ProliaDenosumab | 32 | $55,775 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 37 | $42,469 |
| MounjaroTirzepatide | 31 | $41,987 |
| EliquisApixaban | 43 | $33,692 |
| OzempicSemaglutide | 25 | $29,629 |
| MyrbetriqMirabegron | 27 | $27,105 |
| JanuviaSitagliptin Phosphate | 22 | $24,829 |
| LinzessLinaclotide | 30 | $23,269 |
| FarxigaDapagliflozin Propanediol | 15 | $21,094 |
| LivaloPitavastatin Calcium | 20 | $12,471 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 17 | $10,542 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 45 | $7,518 |
| Breo ElliptaFluticasone/Vilanterol | 14 | $7,296 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $435 | $134,25493 claims |
| Boehringer IngelheimJardiance, Stiolto Respimat | $379 | $112,613118 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $101 | $56,52365 claims |
| AmgenProlia | $14 | $55,77532 claims |
| PfizerEliquis | $48 | $33,69243 claims |
| Novo NordiskOzempic | $241 | $29,62925 claims |
| Astellas Pharma US IncMyrbetriq | $221 | $27,10527 claims |
| MerckJanuvia | $32 | $24,82922 claims |
| AbbVieLinzess | $1,003 | $23,26930 claims |
| AstraZenecaFarxiga | $254 | $21,09415 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $43 | $12,47120 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Arlington
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.